

K102397

FEB 28 2011

**510(k) Summary  
for Kyphon® Xpede™ Bone Cement**

<b>Summary Date:</b>	December 2010
<b>Trade Name:</b>	Kyphon® Xpede™ Bone Cement
<b>Common Name:</b>	PMMA Bone Cement
<b>Classification Name:</b>	Bone Cement (21 CFR part 888.3027)
<b>Device Code, Class:</b>	NDN, Class II
<b>Manufacturer's Name:</b>	Medtronic Spine LLC
<b>Address:</b>	1221 Crossman Avenue Sunnyvale, CA 94089 Establishment Registration No. 2953769
<b>Contact Person:</b>	Mary Rose Sr. Principal Regulatory Affairs Specialist 1221 Crossman Avenue Sunnyvale, CA 94089 Telephone: 408-548-5203 Fax: 408-543-6190
<b>Performance Standards:</b>	The requirements of the Food Drug and Cosmetic Act, under section 514 for performance standards, are not applicable to the KyphX HV-R® Bone Cement.
<b>Predicate Devices:</b>	K093829 KyphX HV- R® Bone Cement K041584 KyphX HV- R® Bone Cement K033801 KyphX HV-R® Bone Cement K060300 Confidence High Viscosity Bone Cement
<b>Intended Use:</b>	KYPHON® Xpede™ Bone Cement is indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a kyphoplasty or vertebroplasty procedure. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung cancer, or lymphoma. Benign lesions include hemangioma and giant cell tumor.

## **510(k) Summary for Kyphon® Xpede™ Bone Cement**

<b>Device Description:</b>	KYPHON® Xpede™ Bone Cement is provided as a two-component system. The powder component consists of a PMMA copolymer (polymethyl methacrylate/methyl-methacrylate-styrene-copolymer) with barium sulfate as a radiopacifier and benzoyl peroxide as an initiator. The liquid component consists of methylmethacrylate monomer, with the addition of hydroquinone as a stabilizer and N,N-dimethyl-p-toluidine as a promoter. The powder and liquid components are mixed prior to use.
<b>Sterilization:</b>	KYPHON® Xpede™ Bone Cement is provided sterile. KYPHON® Xpede™ Bone Cement is intended for single-use only.
<b>Substantial Equivalence:</b>	<p>Testing was conducted to verify the performance of Kyphon® Xpede™ Bone Cement for in vivo applications.</p> <p>The following testing was conducted:</p> <ul style="list-style-type: none"><li>- Mechanical (compressive, tensile, flexural, fatigue)</li><li>- Handling (dough/working time)</li><li>- Physical (viscosity, exotherm, water absorption)</li><li>- Chemical (monomer elution, molecular weight, glass transition temperature)</li><li>- Biocompatibility (cytotoxicity, acute systemic toxicity, intracutaneous reactivity)</li></ul> <p>The results of this testing support the determination of substantial equivalence.</p> <p>Therefore, the modified Kyphon® Xpede™ Bone Cement is substantially equivalent to the predicates, Kyphon HV-R Bone Cement, and Confidence High Viscosity Bone Cement.</p>



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WO66-G609  
Silver Spring, MD 20993-0002

Medtronic Spine LLC  
% Ms. Mary Rose  
Sr. Principal Regulatory Affairs Specialist  
1221 Crossman Avenue  
Sunnyvale, California 94089

FEB 28 2011

Re: K102397

Trade/Device Name: KYPHON® Xpede Bone Cement  
Regulation Number: 21 CFR 888.3027  
Regulation Name: Polymethylmethacrylate (PMMA) bone cement  
Regulatory Class: Class II  
Product Code: NDN  
Dated: February 22, 2011  
Received: February 23, 2011

Dear Ms. Rose:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

Page 2 – Ms. Mary Rose

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Mark N. Melkerson', with a stylized flourish at the end.

Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic  
And Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): \_\_\_\_\_

Device Name: KYPHION® Xpede Bone Cement

### Indications for Use:

Kyphon® Xpede™ Bone Cement is indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a kyphoplasty or vertebroplasty procedure. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung cancer, or lymphoma. Benign lesions include hemangioma and giant cell tumor.

Prescription Use √  
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

Page \_\_ of \_\_

510(k) Number K102397